リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3 (本文)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3 (本文)

早川, 妙香 慶應義塾大学

2021.02.08

概要

PD-1/PD-L1 immune checkpoint inhibitors are promising cancer immunotherapies however responses are still limited and the development of more effective combination immunotherapy is needed. We previously reported that STAT3 activation in cancer cells and immune cells was involved in immune-resistant mechanisms. In this study, we evaluated the effect of highly absorptive forms of curcumin extracts and synthetic curcumin on anti-tumor T cell responses. The curcumin po administration resulted in the significant augmentation of in vivo induction of tumor antigen-specific T cells through restoration of dendritic cells (DCs) by inhibiting directly STAT3 in DCs and indirectly via reduced IL-6 production from STAT3 activated cancer cells in 2 syngeneic MC38 and CT26 murine tumor models. Curcumin also showed direct DC enhancing activity and enhanced T cell induction for the immunized antigens in non-tumor-bearing mice and human hosts. Curcumin restored DC functions in xenogeneic nude mouse model implanted with high IL-6-producing human clear cell ovarian cancer cells. The combination of curcumin and PD-1/PD-L1 Abs demonstrated a synergistic anti-tumor activity in MC38 murine tumor models. These results indicated that curcumin augments the induction of tumor antigen-specific T cells by restoring the T cell stimulatory activity of DCs targeting activated STAT3 in both cancer cells and immune cells. Combination immunotherapy with curcumin and PD-1/PD-L1 Ab is an attractive strategy in the development of effective immunotherapy against various cancers.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immuno- suppressive tumor microenvironments and their personalized mod- ulation. Int Immunol. 2016;28(8):393-399.

2. Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol. 2011;93(3):294-300.

3. Iwata-Kajihara T, Sumimoto H, Kawamura N, et al. Enhanced can- cer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol. 2011;187(1):27-36.

4. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203(7):1651-1656.

5. Lin GS, Yang LJ, Wang XF, et al. STAT3 Tyr705 phosphorylation af- fects clinical outcome in patients with newly diagnosed supratento- rial glioblastoma. Med Oncol. 2014;31(4):924.

6. Shehzad A, Lee J, Lee YS. Curcumin in various cancers. BioFactors. 2013;39(1):56-68.

7. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-818.

8. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative prepara- tion of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-665.

9. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 2013;71(6):1521-1530.

10. Kanai M. Therapeutic applications of curcumin for patients with pancreatic cancer. World J Gastroenterol. 2014;20(28):9384-9391.

11. Nakagawa Y, Mukai S, Yamada S, et al. Short-term effects of high- ly-bioavailable curcumin for treating knee osteoarthritis: a random- ized, double-blind, placebo-controlled prospective study. J Orthop Sci. 2014;19(6):933-939.

12. Tanabe Y, Maeda S, Akazawa N, et al. Attenuation of indirect mark- ers of eccentric exercise-induced muscle damage by curcumin. Eur J Appl Physiol. 2015;115(9):1949-1957.

13. Funamoto M, Sunagawa Y, Katanasaka Y, et al. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2029-2034.

14. Chuah AM, Jacob B, Jie Z, et al. Enhanced bioavailability and bio- efficacy of an amorphous solid dispersion of curcumin. Food Chem. 2014;156:227-233.

15. Nishio H, Yaguchi T, Sugiyama J, et al. Immunosuppression through constitutively activated NF-kappaB signalling in human ovarian cancer and its reversal by an NF-kappaB inhibitor. Br J Cancer. 2014;110(12):2965-2974.

16. Park SJ, Nakagawa T, Kitamura H, et al. IL-6 regulates in vivo den- dritic cell differentiation through STAT3 activation. J Immunol. 2004;173(6):3844-3854.

17. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735-6741.

18. van Dam M, Mullberg J, Schooltink H, et al. Structure-function anal- ysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem. 1993;268(20):15285-15290.

19. Momtazi-Borojeni AA, Abdollahi E, Nikfar B, Chaichian S, Ekhlasi- Hundrieser M. Curcumin as a potential modulator of M1 and M2 macrophages: new insights in atherosclerosis therapy. Heart Fail Rev. 2019;24(3):399-409.

20. Tu SP, Jin H, Shi JD, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interac- tion with cancer cells and related tumor growth. Cancer Prev Res. 2012;5(2):205-215.

21. Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685-6693.

22. Derosa G, Maffioli P, Simental-Mendia LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: a sys- tematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;111:394-404.

23. Lim SO, Li CW, Xia W, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925-939.

24. Liao F, Liu L, Luo E, Hu J. Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. Arch Oral Biol. 2018;92:32-37.

25. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a compo- nent of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32(6):1053-1064.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る